European payers are concerned about orphan drugs citing unjustified high prices and a lack of evidence of utility and value. Pharma has a trust issue with payers, so how can the industry get back on track and gain European payer support for the expanding orphan drug sector?
Payers may have concerns but they also have ideas. We interviewed experienced frontline payers in France, Germany and the UK to reveal in Orphan Drugs: European Payer Perspectives what they see as the key issues and how industry can proactively engage with them.
Payer experts explore key questions
- Should the evidence of clinical effectiveness and safety be less stringent for drugs that are intended to treat rare conditions?
- What factors do payers think manufacturers should take into consideration when setting prices for orphan drugs?
- Is there any justification for manufacturers charging high prices for branded formulations of drugs that are available generically for other indications?
- Should there be a correlation between the annual cost of treatment for an orphan drug and the size of the treatable patient population?
- How can early engagement with payers help to improve planning and manage costs?
- How does national pricing and reimbursement policy and regulation impact on payer perspectives and what does this mean for pharma’s engagement programme?
- What can drug developers do to ensure that orphan drugs will be considered for coverage and reimbursement funding in the future?